News
SGMOQ
0.050
-32.43%
-0.024
Sangamo amends 8-K to file asset purchase agreement exhibits
PUBT · 19h ago
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
Benzinga · 22h ago
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
TipRanks · 23h ago
Sangamo Therapeutics Initiates Chapter 11 and Asset Sales
TipRanks · 1d ago
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce
Benzinga · 1d ago
SANGAMO THERAPEUTICS: EXPECTS RESTRUCTURING TO RESULT IN ELIMINATION OF ABOUT 51 ROLES IN UNITED STATES, OR ABOUT 40% OF COMPANY'S WORKFORCE
Reuters · 1d ago
SANGAMO THERAPEUTICS: ASTELLAS TO BUY CO'S ASSETS FOR $25 MLN PAYABLE AT CLOSING PLUS UP TO EXTRA $25 MLN PAYABLE ON ACHIEVEMENT OF SOME MILESTONES
Reuters · 1d ago
Sangamo lines up up to $30 million debtor-in-possession loan from Northridge ATM amid Chapter 11 filing
PUBT · 1d ago
Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids
PUBT · 1d ago
SANGAMO THERAPEUTICS - ST-503, GIROCTOCOGENE FITELPARVOVEC, AND CELL THERAPY ASSETS REMAIN AVAILABLE FOR BIDDERS
Reuters · 1d ago
Sangamo Therapeutics files for chapter 11 bankruptcy
Seeking Alpha · 1d ago
Weekly Report: what happened at SGMO last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at SGMO last week (0608-0612)?
Weekly Report · 06/15 09:03
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
Benzinga · 06/12 18:40
SANGAMO THERAPEUTICS ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE FOR STAKEHOLDERS
Reuters · 06/08 12:05
Weekly Report: what happened at SGMO last week (0601-0605)?
Weekly Report · 06/08 09:02
Weekly Report: what happened at SGMO last week (0525-0529)?
Weekly Report · 06/01 09:03
Sangamo price target lowered to $5 from $10 at H.C. Wainwright
TipRanks · 05/26 15:59
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/26/26?
TipRanks · 05/26 14:04
Vanguard Total Stock Market (VTI) ETF Latest Update — What Investors Should Know Now
TipRanks · 05/25 13:47
More
Webull provides a variety of real-time SGMOQ stock news. You can receive the latest news about Sangamo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SGMOQ
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.